Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.99 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Protara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 44 | 67 | 47 | 34 | 15 |
Income After Depreciation & Amortization | -44 | -67 | -47 | -34 | -15 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -40 | -66 | -47 | -34 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -40 | -66 | -47 | -34 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -40 | -66 | -47 | -34 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -35 | -46 | -34 | -15 |
Depreciation & Amortization (Cash Flow) | 1 | 32 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -44 | -67 | -47 | -34 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 11.33 | 11.26 | 11.23 | 7.23 | NA |
Diluted EPS Before Non-Recurring Items | -3.57 | -3.24 | -4.21 | -4.70 | NA |
Diluted Net EPS (GAAP) | -3.57 | -5.86 | -4.21 | -4.70 | -30.15 |
Fiscal Year end for Protara Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 10.66 | 11.85 | 11.04 | 10.70 | 12.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.66 | -11.85 | -11.04 | -10.70 | -12.14 |
Non-Operating Income | 1.15 | 0.76 | 0.82 | 0.84 | 0.85 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -9.51 | -11.10 | -10.22 | -9.86 | -11.29 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.51 | -11.10 | -10.22 | -9.86 | -11.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.51 | -11.10 | -10.22 | -9.86 | -11.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 21.23 | 11.42 | 11.37 | 11.35 | 11.31 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.97 | -0.90 | -0.87 | -1.00 |
Diluted Net EPS (GAAP) | -0.45 | -0.97 | -0.90 | -0.87 | -1.00 |